Although it is estimated that COVID-19 life-threatening conditions may be diagnosed in less than 1:1000 infected individuals below the age of 50, but the real impact of this pandemic on pediatric patients with different types of primary immunodeficiency (PID) is not elucidated. The current prospective study on a national registry of PID patients showed that with only 1.23 folds higher incidence of infections, these patients present a 10-folds higher mortality rate compared to population mainly in patients with combined immunodeficiency and immune dysregulation. Therefore, further management modalities against COVID-19 should be considered to improve the survival rate in these two PID entities using hematopoietic stem cell transplantation and immunomodulatory agents.

尽管据估计可能在不到1:50的1：1000感染个体中诊断出可能威胁生命的疾病COVID-19，但是这种大流行对具有不同类型的原发性免疫缺陷（PID）的小儿患者的真正影响不是阐明。目前对PID患者国家注册中心的一项前瞻性研究表明，与感染人群相比，这些患者的感染率仅高出1.23倍，而死亡率则是人群的10倍，主要是免疫缺陷和免疫功能异常的患者。因此，应考虑针对COVID-19的进一步管理方式，以使用造血干细胞移植和免疫调节剂提高这两个PID实体的存活率。